- Home
- PLYA vs DNLI Comparison
PLYA vs DNLI Comparison
Compare PLYA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYA
- DNLI
- Stock Information
- Founded
- PLYA 2006
- DNLI 2013
- Country
- PLYA Netherlands
- DNLI United States
- Employees
- PLYA N/A
- DNLI N/A
- Industry
- PLYA Hotels/Resorts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLYA Consumer Discretionary
- DNLI Health Care
- Exchange
- PLYA Nasdaq
- DNLI Nasdaq
- Market Cap
- PLYA 1.6B
- DNLI 1.9B
- IPO Year
- PLYA N/A
- DNLI 2017
- Fundamental
- Price
- PLYA $13.44
- DNLI $14.37
- Analyst Decision
- PLYA Hold
- DNLI Strong Buy
- Analyst Count
- PLYA 5
- DNLI 15
- Target Price
- PLYA $12.00
- DNLI $33.92
- AVG Volume (30 Days)
- PLYA 2.3M
- DNLI 1.4M
- Earning Date
- PLYA 05-05-2025
- DNLI 05-06-2025
- Dividend Yield
- PLYA N/A
- DNLI N/A
- EPS Growth
- PLYA 8.44
- DNLI N/A
- EPS
- PLYA 0.49
- DNLI N/A
- Revenue
- PLYA $896,462,000.00
- DNLI N/A
- Revenue This Year
- PLYA N/A
- DNLI N/A
- Revenue Next Year
- PLYA $7.68
- DNLI $384.25
- P/E Ratio
- PLYA $27.64
- DNLI N/A
- Revenue Growth
- PLYA N/A
- DNLI N/A
- 52 Week Low
- PLYA $6.95
- DNLI $10.57
- 52 Week High
- PLYA $13.43
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- PLYA 63.16
- DNLI 46.97
- Support Level
- PLYA $13.42
- DNLI $13.36
- Resistance Level
- PLYA $13.45
- DNLI $16.97
- Average True Range (ATR)
- PLYA 0.02
- DNLI 0.95
- MACD
- PLYA -0.00
- DNLI -0.06
- Stochastic Oscillator
- PLYA 80.00
- DNLI 28.08
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company's segments are Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of HYATT ZIVA, HYATT ZILARA, Hilton, JEWEL RESORTS, and others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.